Microbes as medicine.

Fishbein, S. R. S., Mahmud, B., & Dantas, G. (2023). Antibiotic perturbations to the gut microbiome. Nature Reviews Microbiology, 21, 772–788. https://doi.org/10.1038/s41579‐023‐00933‐y

Coyte, K. Z., & Rakoff‐Nahoum, S. (2019). Understanding competition and cooperation within the mammalian gut microbiome. Current Biology, 29, R538–R544. https://doi.org/10.1016/j.cub.2019.04.017

Coyte, K. Z., Schluter, J., & Foster, K. R. (2015). The ecology of the microbiome: Networks, competition, and stability. Science, 350, 663–666. https://doi.org/10.1126/science.aad2602

Culp, E. J., & Goodman, A. L. (2023). Cross‐feeding in the gut microbiome: Ecology and mechanisms. Cell Host & Microbe, 31, 485–499. https://doi.org/10.1016/j.chom.2023.03.016

Wang, S., Mu, L., Yu, C., He, Y., Hu, X., Jiao, Y., Xu, Z., You, S., Liu, S. L., & Bao, H. (2024). Microbial collaborations and conflicts: Unraveling interactions in the gut ecosystem. Gut Microbes, 16, 2296603. https://doi.org/10.1080/19490976.2023.2296603

Faith, J. J., Guruge, J. L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A. L., Clemente, J. C., Knight, R., Heath, A. C., Leibel, R. L., Rosenbaum, M., & Gordon, J. I. (2013). The long‐term stability of the human gut microbiota. Science, 341, 1237439. https://doi.org/10.1126/science.1237439

Mehta, R. S., Abu‐Ali, G. S., Drew, D. A., Lloyd‐Price, J., Subramanian, A., Lochhead, P., Joshi, A. D., Ivey, K. L., Khalili, H., Brown, G. T., Dulong, C., Song, M., Nguyen, L. H., Mallick, H., Rimm, E. B., Izard, J., Huttenhower, C., & Chan, A. T. (2018). Stability of the human faecal microbiome in a cohort of adult men. Nature Microbiology, 3, 347–355. https://doi.org/10.1038/s41564‐017‐0096‐0

Rajilić‐Stojanović, M., Heilig, H. G. H. J., Tims, S., Zoetendal, E. G., & De Vos, W. M. (2012). Long‐term monitoring of the human intestinal microbiota composition. Environmental Microbiology, 15, 1146–1159. https://doi.org/10.1111/1462‐2920.12023

Mitri, S., & Richard Foster, K. (2013). The genotypic view of social interactions in microbial communities. Annual Review of Genetics, 47, 247–273. https://doi.org/10.1146/annurev‐genet‐111212‐133307

Catlett, J. L., Carr, S., Cashman, M., Smith, M. D., Walter, M., Sakkaff, Z., Kelley, C., Pierobon, M., Cohen, M. B., & Buan, N. R. (2022). Metabolic synergy between human symbionts bacteroides and Methanobrevibacter. Microbiology Spectrum, 10, e0106722. https://doi.org/10.1128/spectrum.01067‐22

Ruaud, A., Esquivel‐Elizondo, S., de la Cuesta‐Zuluaga, J., Waters, J. L., Angenent, L. T., Youngblut, N. D., & Ley, R. E. (2020). Syntrophy via interspecies H2 transfer between Christensenella and Methanobrevibacter underlies their global cooccurrence in the human gut. MBio, 11, e03235–19. https://doi.org/10.1128/mBio.03235‐19

Rakoff‐Nahoum, S., Foster, K. R., & Comstock, L. E. (2016). The evolution of cooperation within the gut microbiota. Nature, 533, 255–259. https://doi.org/10.1038/nature17626

David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., Biddinger, S. B., Dutton, R. J., & Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature, 505, 559–563. https://doi.org/10.1038/nature12820

Dethlefsen, L., & Relman, D. A. (2011). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. PNAS, 108(Suppl 1), 4554–4561. https://doi.org/10.1073/pnas.1000087107

Wiles, T. J., Jemielita, M., Baker, R. P., Schlomann, B. H., Logan, S. L., Ganz, J., Melancon, E., Eisen, J. S., Guillemin, K., & Parthasarathy, R. (2016). Host gut motility promotes competitive exclusion within a model intestinal microbiota. PLoS Biology, 14, e1002517. https://doi.org/10.1371/journal.pbio.1002517

Thaiss, C. A., Levy, M., Korem, T., Dohnalová, L., Shapiro, H., Jaitin, D. A., David, E., Winter, D. R., Gury‐Benari, M., Tatirovsky, E., Tuganbaev, T., Federici, S., Zmora, N., Zeevi, D., Dori‐Bachash, M., Pevsner‐Fischer, M., Kartvelishvily, E., Brandis, A., Harmelin, A., … Elinav, E. (2016). Microbiota diurnal rhythmicity programs host transcriptome oscillations. Cell, 167, 1495–1510.e12 e1412. https://doi.org/10.1016/j.cell.2016.11.003

Bauer, E., & Thiele, I. (2018). From network analysis to functional metabolic modeling of the human gut microbiota. Msystems, 3, e00209‐17. https://doi.org/10.1128/mSystems.00209‐17

Coulthurst, S. (2019). The type VI secretion system: A versatile bacterial weapon. Microbiology (N Y Reading), 165, 503–515. https://doi.org/10.1099/mic.0.000789

Bottai, D., Groschel, M. I., & Brosch, R. (2017). Type VII secretion systems in gram‐positive bacteria. Current Topics in Microbiology and Immunology, 404, 235–265. https://doi.org/10.1007/82_2015_5015

Gu, Q., Yan, J., Lou, Y., Zhang, Z., Li, Y., Zhu, Z., Liu, M., Wu, D., Liang, Y., Pu, J., Zhao, X., Xiao, H., & Li, P. (2024). Bacteriocins: Curial guardians of gastrointestinal tract. Comprehensive Reviews in Food Science and Food Safety, 23, e13292. https://doi.org/10.1111/1541‐4337.13292

Ezzedine, J. A., Desdevises, Y., & Jacquet, S. (2022). Bdellovibrio and like organisms: Current understanding and knowledge gaps of the smallest cellular hunters of the microbial world. Critical Reviews in Microbiology, 48, 428–449. https://doi.org/10.1080/1040841X.2021.1979464

Lambert, C., Morehouse, K. A., Chang, C. Y., & Sockett, R. E. (2006). Bdellovibrio: Growth and development during the predatory cycle. Current Opinion in Microbiology, 9, 639–644. https://doi.org/10.1016/j.mib.2006.10.002

Iebba, V., Santangelo, F., Totino, V., Nicoletti, M., Gagliardi, A., De Biase, R. V., Cucchiara, S., Nencioni, L., Conte, M. P., & Schippa, S. (2013). Higher prevalence and abundance of Bdellovibrio bacteriovorus in the human gut of healthy subjects. PLoS ONE, 8, e61608. https://doi.org/10.1371/journal.pone.0061608

Shkoporov, A. N., & Hill, C. (2019). Bacteriophages of the human gut: The “known unknown” of the microbiome. Cell Host & Microbe, 25, 195–209. https://doi.org/10.1016/j.chom.2019.01.017

Chabé, M., Lokmer, A., & Ségurel, L. (2017). Gut protozoa: Friends or foes of the human gut microbiota? Trends in Parasitology, 33, 925–934. https://doi.org/10.1016/j.pt.2017.08.005

Levy, R., & Borenstein, E. (2013). Metabolic modeling of species interaction in the human microbiome elucidates community‐level assembly rules. PNAS, 110, 12804–12809. https://doi.org/10.1073/pnas.1300926110

Patnode, M. L., Beller, Z. W., Han, N. D., Cheng, J., Peters, S. L., Terrapon, N., Henrissat, B., Le Gall, S., Saulnier, L., Hayashi, D. K., Meynier, A., Vinoy, S., Giannone, R. J., Hettich, R. L., & Gordon, J. I. (2019). Interspecies competition impacts targeted manipulation of human gut bacteria by fiber‐derived glycans. Cell, 179, 59–73. https://doi.org/10.1016/j.cell.2019.08.011

Holdridge, E. M., Cuellar‐Gempeler, C., & Terhorst, C. P. (2016). A shift from exploitation to interference competition with increasing density affects population and community dynamics. Ecology & Evolution, 6, 5333–5341. https://doi.org/10.1002/ece3.2284

Askarova, S., Umbayev, B., Masoud, A. R., Kaiyrlykyzy, A., Safarova, Y., Tsoy, A., Olzhayev, F., & Kushugulova, A. (2020). The links between the gut microbiome, aging, modern lifestyle and Alzheimer's disease. Frontiers in Cellular and Infection Microbiology, 10, 104. https://doi.org/10.3389/fcimb.2020.00104

Collins, S. L., & Patterson, A. D. (2020). The gut microbiome: An orchestrator of xenobiotic metabolism. Acta Pharmaceutica Sinica B, 10, 19–32. https://doi.org/10.1016/j.apsb.2019.12.001

Mohammadkhah, A. I., Simpson, E. B., Patterson, S. G., & Ferguson, J. F. (2018). Development of the gut microbiome in children, and lifetime implications for obesity and cardiometabolic disease. Children (Basel), 5, 160. https://doi.org/10.3390/children5120160

Zmora, N., Zilberman‐Schapira, G., Suez, J., Mor, U., Dori‐Bachash, M., Bashiardes, S., Kotler, E., Zur, M., Regev‐Lehavi, D., Brik, R. B.‐Z., Federici, S., Cohen, Y., Linevsky, R., Rothschild, D., Moor, A. E., Ben‐Moshe, S., Harmelin, A., Itzkovitz, S., Maharshak, N., … Elinav, E. (2018). Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell, 174, 1388–1405. https://doi.org/10.1016/j.cell.2018.08.041

Crost, E. H., Coletto, E., Bell, A., & Juge, N. (2023). Ruminococcus gnavus: Friend or foe for human health. FEMS Microbiology Review, 47, fuad014. https://doi.org/10.1093/femsre/fuad014

Robinson, J. I., Weir, W. H., Crowley, J. R., Hink, T., Reske, K. A., Kwon, J. H., Burnham, C. D., Dubberke, E. R., Mucha, P. J., & Henderson, J. P. (2019). Metabolomic networks connect host‐microbiome processes to human Clostridioides difficile infections. Journal of Clinical Investigation, 129, 3792–3806. https://doi.org/10.1172/JCI126905

Antunes, L. C. M., Mcdonald, J. A. K., Schroeter, K., Carlucci, C., Ferreira, R. B., Wang, M., Yurist‐Doutsch, S., Hira, G., Jacobson, K., Davies, J., Allen‐Vercoe, E., & Finlay, B. B. (2014). Antivirulence activity of the human gut metabolome. MBio, 5, e01183–14. https://doi.org/10.1128/mBio.01183‐14

Pauer, H., Teixeira, F. L., Robinson, A. V., Parente, T. E., De Melo, M. A. F., Lobo, L. A., Domingues, R., Allen‐Vercoe, E., Ferreira, R. B. R., & Antunes, L. C. M. (2021). Bioactive small molecules produced by the human gut microbiome modulate Vibrio cholerae sessile and planktonic lifestyles. Gut Microbes, 13, 1–19. https://doi.org/10.1080/19490976.2021.1918993

Chen, Y. (2007). Inverse associations of Helicobacter pylori with asthma and allergy. Archives of Internal Medicine, 167, 821–827. https://doi.org/10.1001/archinte.167.8.821

Cover, T. L., & Blaser, M. J. (2009). Helicobacter pylori in health and disease. Gastroenterology, 136, 1863–1873. https://doi.org/10.1053/j.gastro.2009.01.073

Edwards, A. M., Grossman, T. J., & Rudney, J. D. (2006). Fusobacterium nucleatum transports noninvasive Streptococcus cristatus into human epithelial cells. Infection and Immunity, 74, 654–662. https://doi.org/10.1128/IAI.74.1.654‐662.2006

Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, R. B., Flint, H. J., Salminen, S., Calder, P. C., & Sanders, M. E. (2014). Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology, 11, 506–514. https://doi.org/10.1038/nrgastro.2014.66

Metchnikoff, E. (1908). The prolongation of life: optimistic studies. G.P. Putnam's Sons.

Fagnant, H. S., Isidean, S. D., Wilson, L., Bukhari, A. S., Allen, J. T., Agans, R. T., Lee, D. M., Hatch‐McChesney, A., Whitney, C. C., Sullo, E., Porter, C. K., & Karl, J. P. (2023). Orally ingested probiotic, prebiotic, and synbiotic interventions as countermeasures for gastrointestinal tract infections in nonelderly adults: A systematic review and meta‐analysis. Advances in Nutrition, 14, 539–554. https://doi.org/10.1016/j.advnut.2023.02.002

Mousavi Khaneghah, A., Abhari, K., Eş, I., Soares, M. B., Oliveira, R. B. A., Hosseini, H., Rezaei, M., Balthazar, C. F., Silva, R., Cruz, A. G., Ranadheera, C. S., & Sant'Ana, A. S. (2020). Interactions between probiotics and pathogenic microorganisms in hosts and foods: A review. Trends in Food Science & Technology, 95, 205–218. https://doi.org/10.1016/j.tifs.2019.11.022

Reid, G., & Friendship, R. (2002). Alternatives to antibiotic use: Probiotics for the gut. Animal Biotechnology, 13, 97–112. https://doi.org/10.1081/ABIO‐120005773

Reid, G., Jass, J., Sebulsky, M. T., & McCormick, J. K. (2003). Potential uses of probiotics in clinical practice. Clinical Microbiology Reviews, 16, 658–672. https://doi.org/10.1128/CMR.16.4.658‐672.2003

Kristensen, N. B., Bryrup, T., Allin, K. H., Nielsen, T., Hansen, T. H., & Pedersen, O. (2016). Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: A systematic review of randomized controlled trials. Genome Medicine, 8, 52. https://doi.org/10.1186/s13073‐016‐0300‐5

Vélez, M. P., Petrova, M. I., Lebeer, S., Verhoeven, T. L. A., Claes, I., Lambrichts, I., Tynkkynen, S., Vanderleyden, J., & De Keersmaecker, S. C. J. (2010). Characterization of MabA, a modulator of Lactobacillus rhamnosus GG adhesion and biofilm formation. FEMS Immunology and Medical Microbiology, 59, 386–398. https://doi.org/10.1111/j.1574‐695X.2010.00680.x

von Ossowski, I., Satokari, R., Reunanen, J., Lebeer, S., De Keersmaecker, S. C., Vanderleyden, J., de Vos, W. M., & Palva, A. (2011). Functional characterization of a mucus‐specific LPXTG surface adhesin from probiotic Lactobacillus rhamnosus GG. Applied and Environmental Microbiology, 77, 4465–4472. https://doi.org/10.1128/AEM.02497‐10

Lebeer, S., Claes, I., Tytgat, H. L. P., Verhoeven, T. L. A., Marien, E., Von Ossowski, I., Reunanen, J., Palva, A., De Vos, W. M., De Keersmaecker, S. C. J., & Vanderleyden, J. (2012). Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Applied and Environmental Microbiology, 78, 185–193. https://doi.org/10.1128/AEM.06192‐11

Cheng, V. C., Chen, J. H., Tai, J. W., Wong, S. C., Poon, R. W., Hung, I. F., To, K. K., Chan, J. F., Ho, P. L., Lo, C. M., & Yuen, K. Y. (2014). Decolonization of gastrointestinal carriage of vancomycin‐resistant Enterococcus faecium: Case series and review of literature. BMC Infectious Diseases [Electronic Resource], 14, 514. https://doi.org/10.1186/1471‐2334‐14‐514

Tytgat, H. L., Douillard, F. P., Reunanen, J., Rasinkangas, P., Hendrickx, A. P., Laine, P. K., Paulin, L., Satokari, R., & de Vos, W. M. (2016). Lactobacillus rhamnosus GG outcompetes Enterococcus faecium via mucus‐binding pili: Evidence for a novel and heterospecific probiotic mechanism. Applied and Environmental Microbiology, 82, 5756–5762. https://doi.org/10.1128/AEM.01243‐16

Tuomola, E. M., Ouwehand, A. C., & Salminen, S. J. (1999). The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunology and Medical Microbiology, 26, 137–142. https://doi.org/10.1111/j.1574‐695X.1999.tb01381.x

Kankainen, M., Paulin, L., Tynkkynen, S., Von Ossowski, I., Reunanen, J., Partanen, P., Satokari, R., Vesterlund, S., Hendrickx, A. P. A., Lebeer, S., De Keersmaecker, S. C. J., Vanderleyden, J., Hämäläinen, T., Laukkanen, S., Salovuori, N., Ritari, J., Alatalo, E., Korpela, R., Mattila‐Sandholm, T., … De Vos, W. M. (2009). Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human‐ mucus binding protein. PNAS, 106, 17193–17198. https://doi.org/10.1073/pnas.0908876106

You, L., Lv, R., Jin, H., Ma, T., Zhao, Z., Kwok, L. Y., & Sun, Z. (2023). A large‐scale comparative genomics study reveals niche‐driven and within‐sample intra‐species functional diversification in Lacticaseibacillus rhamnosus. Food Research International, 173, 113446. https://doi.org/10.1016/j.foodres.2023.113446

Lebeer, S., Bron, P. A., Marco, M. L., Van Pijkeren, J.‐P., O'connell Motherway, M., Hill, C., Pot, B., Roos, S., & Klaenhammer, T. (2018). Identification of probiotic effector molecules: Present state and future perspectives. Current Opinion in Biotechnology, 49, 217–223. https://doi.org/10.1016/j.copbio.2017.10.007

Shen, N. T., Maw, A., Tmanova, L. L., Pino, A., Ancy, K., Crawford, C. V., Simon, M. S., & Evans, A. T. (2017). Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: A systematic review with meta‐regression analysis. Gastroenterology, 152, 1889–1900. https://doi.org/10.1053/j.gastro.2017.02.003

Ferrario, C., Taverniti, V., Milani, C., Fiore, W., Laureati, M., De Noni, I., Stuknyte, M., Chouaia, B., Riso, P., & Guglielmetti, S. (2014). Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. Journal of Nutrition, 144, 1787–1796. https://doi.org/10.3945/jn.114.197723

Maldonado‐Gómez, M. X., Martínez, I., Bottacini, F., O'callaghan, A., Ventura, M., Van Sinderen, D., Hillmann, B., Vangay, P., Knights, D., Hutkins, R. W., & Walter, J. (2016). Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host & Microbe, 20, 515–526. https://doi.org/10.1016/j.chom.2016.09.001

de Simone, C. (2019). The unregulated probiotic market. Clinical Gastroenterology and Hepatology, 17, 809–817. https://doi.org/10.1016/j.cgh.2018.01.018

Jackson, S. A., Schoeni, J. L., Vegge, C., Pane, M., Stahl, B., Bradley, M., Goldman, V. S., Burguière, P., Atwater, J. B., & Sanders, M. E. (2019). Improving end‐user trust in the quality of commercial probiotic products. Frontiers in Microbiology, 10, 739. https://doi.org/10.3389/fmicb.2019.00739

Suez, J., Zmora, N., Zilberman‐Schapira, G., Mor, U., Dori‐Bachash, M., Bashiardes, S., Zur, M., Regev‐Lehavi, D., Ben‐Zeev Brik, R., Federici, S., Horn, M., Cohen, Y., Moor, A. E., Zeevi, D., Korem, T., Kotler, E., Harmelin, A., Itzkovitz, S., Maharshak, N., … Elinav, E. (2018). Post‐antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell, 174, 1406–1423. https://doi.org/10.1016/j.cell.2018.08.047

Sanders, M. E., Merenstein, D. J., Ouwehand, A. C., Reid, G., Salminen, S., Cabana, M. D., Paraskevakos, G., & Leyer, G. (2016). Probiotic use in at‐risk populations. Journal of the American Pharmacists Association (2003), 56, 680–686. https://doi.org/10.1016/j.japh.2016.07.001

FDA. (2023). FDA raises concerns about probiotic products sold for use in hospitalized preterm infants. FDA. https://www.fda.gov/news‐events/press‐announcements/fda‐raises‐concerns‐about‐probiotic‐products‐sold‐use‐hospitalized‐preterm‐infants

Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., Verbeke, K., & Reid, G. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology, 14, 491–502. https://doi.org/10.1038/nrgastro.2017.75

Parsons, B. N., Wigley, P., Simpson, H. L., Williams, J. M., Humphrey, S., Salisbury, A.‐M., Watson, A. J. M., Fry, S. C., O'brien, D., Roberts, C. L., O'kennedy, N., Keita, Å. V., Söderholm, J. D., Rhodes, J. M., & Campbell, B. J. (2014). Dietary supplementation with soluble plantain non‐starch polysaccharides inhibits intestinal invasion of Salmonella Typhimurium in the chicken. PLoS ONE, 9, e87658. https://doi.org/10.1371/journal.pone.0087658

Roberts, C. L., Keita, Å. V., Parsons, B. N., Prorok‐Hamon, M., Knight, P., Winstanley, C., O′Kennedy, N., Söderholm, J. D., Rhodes, J. M., & Campbell, B. J. (2013). Soluble plantain fibre blocks adhesion and M‐cell translocation of intestinal pathogens. Journal of Nutritional Biochemistry, 24, 97–103. https://doi.org/10.1016/j.jnutbio.2012.02.013

Simpson, H. L., & Campbell, B. J. (2015). Review article: Dietary fibre‐microbiota interactions. Alimentary Pharmacology & Therapeutics, 42, 158–179. https://doi.org/10.1111/apt.13248

Ribeiro, M. C., Levi, Y., Moraschini, V., Messora, M. R., & Furlaneto, F. A. C. (2024). Effects of prebiotic therapy on gastrointestinal microbiome of individuals with different inflammatory conditions: A systematic review of randomized controlled trials. Probiotics and Antimicrobial Proteins, 16, 673–695. https://doi.org/10.1007/s12602‐023‐10075‐5

Tsukuda, N., Yahagi, K., Hara, T., Watanabe, Y., Matsumoto, H., Mori, H., Higashi, K., Tsuji, H., Matsumoto, S., Kurokawa, K., & Matsuki, T. (2021). Key bacterial taxa and metabolic pathways affecting gut short‐chain fatty acid profiles in early life. The ISME Journal, 15, 2574–2590. https://doi.org/10.1038/s41396‐021‐00937‐7

Kumar, H., Collado, M. C., Wopereis, H., Salminen, S., Knol, J., & Roeselers, G. (2020). The bifidogenic effect revisited‐ecology and health perspectives of bifidobacterial colonization in early life. Microorganisms, 8, 1855. https://doi.org/10.3390/microorganisms8121855

Sakanaka, M., Hansen, M. E., Gotoh, A., Katoh, T., Yoshida, K., Odamaki, T., Yachi, H., Sugiyama, Y., Kurihara, S., Hirose, J., Urashima, T., Xiao, J.‐Z., Kitaoka, M., Fukiya, S., Yokota, A., Lo Leggio, L., Abou Hachem, M., & Katayama, T. (2019). Evolutionary adaptation in fucosyllactose uptake systems supports bifidobacteria‐infant symbiosis. Science Advances, 5, eaaw7696. https://doi.org/10.1126/sciadv.aaw7696

Andrews, P., & Johnson, R. J. (2020). Evolutionary basis for the human diet: Consequences for human health. Journal of Internal Medicine, 287, 226–237. https://doi.org/10.1111/joim.13011

Plamada, D., & Vodnar, D. C. (2021). Polyphenols‐gut microbiota interrelationship: A transition to a new generation of prebiotics. Nutrients, 14, 137. https://doi.org/10.3390/nu14010137

Rana, A., Samtiya, M., Dhewa, T., Mishra, V., & Aluko, R. E. (2022). Health benefits of polyphenols: A concise review. Journal of Food Biochemistry, 46, e14264. https://doi.org/10.1111/jfbc.14264

Villeneuve, C., Kou, H. H., Eckermann, H., Palkar, A., Anderson, L. G., McKenney, E. A., Bollinger, R. R., & Parker, W. (2018). Evolution of the hygiene hypothesis into biota alteration theory: What are the paradigms and where are the clinical applications? Microbes and Infection, 20, 147–155. https://doi.org/10.1016/j.micinf.2017.11.001

Mills, J. G., Weinstein, P., Gellie, N. J., Weyrich, L. S., Lowe, A. J., & Breed, M. F. (2017). Urban habitat restoration provides a human health benefit through microbiome rewilding: The microbiome rewilding hypothesis. Restoration Ecology, 25, 866–872. https://doi.org/10.1111/rec.12610

Holmes, Z. C., Villa, M. M., Durand, H. K., Jiang, S., Dallow, E. P., Petrone, B. L., Silverman, J. D., Lin, P. H., & David, L. A. (2022). Microbiota responses to different prebiotics are conserved within individuals and associated with habitual fiber intake. Microbiome, 10, 114. https://doi.org/10.1186/s40168‐022‐01307‐x

Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., & Sanders, M. E. (2020). The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nature Reviews Gastroenterology & Hepatology, 17, 687–701. https://doi.org/10.1038/s41575‐020‐0344‐2

Phavichitr, N., Wang, S., Chomto, S., Tantibhaedhyangkul, R., Kakourou, A., Intarakhao, S., Jongpiputvanich, S., Wongteerasut, A., Ben‐Amor, K., Martin, R., Ting, S., Suteerojntrakool, O., Visuthranukul, C., Piriyanon, P., Roeselers, G., & Knol, J. (2021). Impact of synbiotics on gut microbiota during early life: A randomized, double‐blind study. Scientific Reports, 11, 3534. https://doi.org/10.1038/s41598‐021‐83009‐2

Button, J. E., Autran, C. A., Reens, A. L., Cosetta, C. M., Smriga, S., Ericson, M., Pierce, J. V., Cook, D. N., Lee, M. L., Sun, A. K., Alousi, A. M., Koh, A. Y., Rechtman, D. J., Jenq, R. R., & Mckenzie, G. J. (2022). Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics. Cell Host & Microbe, 30, 712–725.e7. https://doi.org/10.1016/j.chom.2022.04.001

Kondepudi, K. K., Ambalam, P., Nilsson, I., Wadström, T., & Ljungh, Å. (2012). Prebiotic‐non‐digestible oligosaccharides preference of probiotic bifidobacteria and antimicrobial activity against Clostridium difficile. Anaerobe, 18, 489–497. https://doi.org/10.1016/j.anaerobe.2012.08.005

Korur, S. S., Chowdhury, R., & Bhattacharya, P. (2016). Potentiation of functional and antimicrobial activities through synergistic growth of probiotic Pediococcus acidilactici with natural prebiotics (garlic, basil). Microbes Spotlight, 28, 219–224.

Skonieczna‐Żydecka, K., Kaczmarczyk, M., Łoniewski, I., Lara, L. F., Koulaouzidis, A., Misera, A., Maciejewska, D., & Marlicz, W. (2018). A systematic review, meta‐analysis, and meta‐regression evaluating the efficacy and mechanisms of action of probiotics and synbiotics in the prevention of surgical site infections and surgery‐related complications. Journal of Clinical Medicine, 7, 556. https://doi.org/10.3390/jcm7120556

Centurion, F., Basit, A. W., Liu, J., Gaisford, S., Rahim, M. A., & Kalantar‐Zadeh, K. (2021). Nanoencapsulation for probiotic delivery. ACS Nano, 15, 18653–18660. https://doi.org/10.1021/acsnano.1c09951

Staudacher, H. M., & Whelan, K. (2017). The low FODMAP diet: Recent advances in understanding its mechanisms and efficacy in IBS. Gut, 66, 1517–1527. https://doi.org/10.1136/gutjnl‐2017‐313750

Trush, E. A., Poluektova, E. A., Beniashvilli, A. G., Shifrin, O. S., Poluektov, Y. M., & Ivashkin, V. T. (2020). The evolution of human probiotics: Challenges and prospects. Probiotics and Antimicrobial Proteins, 12, 1291–1299. https://doi.org/10.1007/s12602‐019‐09628‐4

Xu, C., Ban, Q., Wang, W., Hou, J., & Jiang, Z. (2022). Novel nano‐encapsulated probiotic agents: Encapsulate materials, delivery, and encapsulation systems. Journal of Controlled Release, 349, 184–205. https://doi.org/10.1016/j.jconrel.2022.06.061

Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., & Vinderola, G. (2021). The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology & Hepatology, 18, 649–667. https://doi.org/10.1038/s41575‐021‐00440‐6

Ma, L., Tu, H., & Chen, T. (2023). Postbiotics in human health: A narrative review. Nutrients, 15, 291. https://doi.org/10.3390/nu15020291

de Almada, C. N., Almada, C. N., Martinez, R. C. R., & Sant'Ana, A. S. (2016). Paraprobiotics: Evidences on their ability to modify biological responses, inactivation methods and perspectives on their application in foods. Trends in Food Science & Technology, 58, 96–114. https://doi.org/10.1016/j.tifs.2016.09.011

Taverniti, V., & Guglielmetti, S. (2011). The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: Proposal of paraprobiotic concept). Genes & Nutrition, 6, 261–274. https://doi.org/10.1007/s12263‐011‐0218‐x

Warda, A. K., Rea, K., Fitzgerald, P., Hueston, C., Gonzalez‐Tortuero, E., Dinan, T. G., & Hill, C. (2019). Heat‐killed lactobacilli alter both microbiota composition and behaviour. Behavioural Brain Research, 362, 213–223. https://doi.org/10.1016/j.bbr.2018.12.047

Meng, D., Sommella, E., Salviati, E., Campiglia, P., Ganguli, K., Djebali, K., Zhu, W., & Walker, W. A. (2020). Indole‐3‐lactic acid, a metabolite of tryptophan, secreted by Bifidobacterium longum subspecies infantis is anti‐inflammatory in the immature intestine. Pediatric Research, 88, 209–217. https://doi.org/10.1038/s41390‐019‐0740‐x

Kolba, N., & Tako, E. (2023). Effective alternatives for dietary interventions for necrotizing enterocolitis: A systematic review of in vivo studies. Critical Reviews in Food Science and Nutrition, 63, 1–21. https://doi.org/10.1080/10408398.2023.2281623

Hernández‐Granados, M. J., & Franco‐Robles, E. (2020). Postbiotics in human health: Possible new functional ingredients? Food Research International, 137, 109660. https://doi.org/10.1016/j.foodres.2020.109660

Leblanc, J. G., Chain, F., Martín, R., Bermúdez‐Humarán, L. G., Courau, S., & Langella, P. (2017). Beneficial effects on host energy metabolism of short‐chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microbial Cell Factories, 16, 79. https://doi.org/10.1186/s12934‐017‐0691‐z

Ozma, M. A., Moaddab, S. R., Hosseini, H., Khodadadi, E., Ghotaslou, R., Asgharzadeh, M., Abbasi, A., Kamounah, F. S., Aghebati Maleki, L., Ganbarov, K., & Samadi Kafil, H. (2023). A critical review of novel antibiotic resistance prevention approaches with a focus on postbiotics. Critical Reviews in Food Science and Nutrition, 63, 1–19. https://doi.org/10.1080/10408398.2023.2214818

Cicenia, A., Scirocco, A., Carabotti, M., Pallotta, L., Marignani, M., & Severi, C. (2014). Postbiotic activities of lactobacilli‐derived factors. Journal of Clinical Gastroenterology, 48(Suppl 1), S18–S22. https://doi.org/10.1097/MCG.0000000000000231

Warda, A. K., Clooney, A. G., Ryan, F., de Almeida Bettio, P. H., Di Benedetto, G., Ross, R. P., & Hill, C. (2021). A postbiotic consisting of heat‐treated lactobacilli has a bifidogenic effect in pure culture and in human fermented faecal communities. Applied and Environmental Microbiology, 87, e02459–20. https://doi.org/10.1128/AEM.02459‐20

Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in the age of multi‐drug resistance. World Journal of Gastrointestinal Pharmacology and Therapeutics, 8, 162–173. https://doi.org/10.4292/wjgpt.v8.i3.162

Hahn, A., Sami, I., Chaney, H., Koumbourlis, A. C., Del Valle Mojica, C., Cochrane, C., Chan, B. K., & Koff, J. L. (2023). Bacteriophage therapy for pan‐drug‐resistant Pseudomonas aeruginosa in two persons with cystic fibrosis. Journal of Investigative Medicine High Impact Case Reports, 11, 23247096231188243. https://doi.org/10.1177/23247096231188243

Law, N., Logan, C., Yung, G., Furr, C.‐L. L., Lehman, S. M., Morales, S., Rosas, F., Gaidamaka, A., Bilinsky, I., Grint, P., Schooley, R. T., & Aslam, S. (2019). Successful adjunctive use of bacteriophage therapy for treatment of multidrug‐resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection, 47, 665–668. https://doi.org/10.1007/s15010‐019‐01319‐0

Karn, S. L., Bhartiya, S. K., Pratap, A., Saroj, S. K., Kumar, R., Sahu, M., Gangwar, M., & Nath, G. (2024). A randomized, placebo‐controlled, double‐blind clinical trial of bacteriophage cocktails in chronic wound infections. The International Journal of Lower Extremity Wounds, 23, 15347346231226342. https://doi.org/10.1177/15347346231226342

Lungren, M. P., Christensen, D., Kankotia, R., Falk, I., Paxton, B. E., & Kim, C. Y. (2013). Bacteriophage K for reduction of Staphylococcus aureus biofilm on central venous catheter material. Bacteriophage, 3, e26825. https://doi.org/10.4161/bact.26825

Tkhilaishvili, T., Lombardi, L., Klatt, A. B., Trampuz, A., & Di Luca, M. (2018). Bacteriophage Sb‐1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus. International Journal of Antimicrobial Agents, 52, 842–853. https://doi.org/10.1016/j.ijantimicag.2018.09.006

Zhang, Y., Cheng, M., Zhang, H., Dai, J., Guo, Z., Li, X., Ji, Y., Cai, R., Xi, H., Wang, X., Xue, Y., Sun, C., Feng, X., Lei, L., Han, W., & Gu, J. (2018). Antibacterial effects of phage lysin LysGH15 on planktonic cells and biofilms of diverse staphylococci. Applied and Environmental Microbiology, 84, e00886–18. https://doi.org/10.1128/AEM.00886‐18

Stacey, H. J., De Soir, S., & Jones, J. D. (2022). The safety and efficacy of phage therapy: A systematic review of clinical and safety trials. Antibiotics (Basel), 11, 1340. https://doi.org/10.3390/antibiotics11101340

Uyttebroek, S., Chen, B., Onsea, J., Ruythooren, F., Debaveye, Y., Devolder, D., Spriet, I., Depypere, M., Wagemans, J., Lavigne, R., Pirnay, J.‐P., Merabishvili, M., De Munter, P., Peetermans, W. E., Dupont, L., Van Gerven, L., & Metsemakers, W.‐J. (2022). Safety and efficacy of phage therapy in difficult‐to‐treat infections: A systematic review. The Lancet Infectious Diseases, 22, e208–e220. https://doi.org/10.1016/S1473‐3099(21)00612‐5

Rostøl, J. T., & Marraffini, L. (2019). (Ph)ighting phages: How bacteria resist their parasites. Cell Host & Microbe, 25, 184–194. https://doi.org/10.1016/j.chom.2019.01.009

Schooley, R. T., Biswas, B., Gill, J. J., Hernandez‐Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., Segall, A. M., Taplitz, R., Smith, D. M., Kerr, K., Kumaraswamy, M., Nizet, V., Lin, L., Mccauley, M. D., Strathdee, S. A., … Hamilton, T. (2017). Development and use of personalized bacteriophage‐based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrobial Agents and Chemotherapy, 61, e00954–17. https://doi.org/10.1128/AAC.00954‐17

Gan, L., Feng, Y., Du, B., Fu, H., Tian, Z., Xue, G., Yan, C., Cui, X., Zhang, R., Cui, J., Zhao, H., Feng, J., Xu, Z., Fan, Z., Fu, T., Du, S., Liu, S., Zhang, Q., Yu, Z., … Yuan, J. (2023). Bacteriophage targeting microbiota alleviates non‐alcoholic fatty liver disease induced by high alcohol‐producing Klebsiella pneumoniae. Nature Communications, 14, 3215. https://doi.org/10.1038/s41467‐023‐39028‐w

Duan, Y., Llorente, C., Lang, S., Brandl, K., Chu, H., Jiang, L., White, R. C., Clarke, T. H., Nguyen, K., Torralba, M., Shao, Y., Liu, J., Hernandez‐Morales, A., Lessor, L., Rahman, I. R., Miyamoto, Y., Ly, M., Gao, B., Sun, W., … Schnabl, B. (2019). Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 575, 505–511. https://doi.org/10.1038/s41586‐019‐1742‐x

Airola, C., Severino, A., Porcari, S., Fusco, W., Mullish, B. H., Gasbarrini, A., Cammarota, G., Ponziani, F. R., & Ianiro, G. (2023). Future modulation of gut microbiota: From eubiotics to FMT, engineered bacteria, and phage therapy. Antibiotics (Basel), 12, 868. https://doi.org/10.3390/antibiotics12050868

Bertozzi Silva, J., Storms, Z., & Sauvageau, D. (2016). Host receptors for bacteriophage adsorption. FEMS Microbiology Letters, 363, fnw002. https://doi.org/10.1093/femsle/fnw002

Lenneman, B. R., Fernbach, J., Loessner, M. J., Lu, T. K., & Kilcher, S. (2021). Enhancing phage therapy through synthetic biology and genome engineering. Current Opinion in Biotechnology, 68, 151–159. https://doi.org/10.1016/j.copbio.2020.11.003

Zhang, F., Luo, W., Shi, Y., Fan, Z., & Ji, G. (2012). Should we standardize the 1,700‐year‐old fecal microbiota transplantation? American Journal of Gastroenterology, 107, 1755–1756. https://doi.org/10.1038/ajg.2012.251

Eiseman, B., Silen, W., Bascom, G. S., & Kauvar, A. J. (1958). Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 44, 854–859.

Kelly, C. R., Khoruts, A., Staley, C., Sadowsky, M. J., Abd, M., Alani, M., Bakow, B., Curran, P., Mckenney, J., Tisch, A., Reinert, S. E., Machan, J. T., & Brandt, L. J. (2016). Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: A randomized trial. Annals of Internal Medicine, 165, 609–616. https://doi.org/10.7326/M16‐0271

Quraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. (2017). Systematic review with meta‐analysis: The efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary Pharmacology & Therapeutics, 46, 479–493. https://doi.org/10.1111/apt.14201

El Hage Chehade, N., Ghoneim, S., Shah, S., Chahine, A., Mourad, F. H., Francis, F. F., Binion, D. G., Farraye, F. A., & Hashash, J. G. (2023). Efficacy of fecal microbiota transplantation in the treatment of active ulcerative colitis: A systematic review and meta‐analysis of double‐blind randomized controlled trials. Inflammatory Bowel Diseases, 29, 808–817. https://doi.org/10.1093/ibd/izac135

Wu, J., Lv, L., & Wang, C. (2022). Efficacy of fecal microbiota transplantation in irritable bowel syndrome: A meta‐analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology, 12, 827395. https://doi.org/10.3389/fcimb.2022.827395

Craven, L., Rahman, A., Nair Parvathy, S., Beaton, M., Silverman, J., Qumosani, K., Hramiak, I., Hegele, R., Joy, T., Meddings, J., Urquhart, B., Harvie, R., Mckenzie, C., Summers, K., Reid, G., Burton, J. P., & Silverman, M. (2020). Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. American Journal of Gastroenterology, 115, 1055–1065. https://doi.org/10.14309/ajg.0000000000000661

Al, K. F., Craven, L. J., Gibbons, S., Parvathy, S. N., Wing, A. C., Graf, C., Parham, K. A., Kerfoot, S. M., Wilcox, H., Burton, J. P., Kremenchutzky, M., Morrow, S. A., Casserly, C., Meddings, J., Sharma, M., & Silverman, M. S. (2022). Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial. Multiple Sclerosis Journal ‐ Experimental Translational and Clinical, 8, 205521732210866. https://doi.org/10.1177/20552173221086662

Hazan, S. (2020). Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: A case report. Journal of International Medical Research, 48, 030006052092593. https://doi.org/10.1177/0300060520925930

Fan, L., Ren, J., Chen, Y., Wang, Y., Guo, Z., Bu, P., Yang, J., Ma, W., Zhu, B., Zhao, Y., & Cai, J. (2022). Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: Protocol of a randomized, blinded, placebo‐controlled study. Trials, 23, 178. https://doi.org/10.1186/s13063‐022‐06086‐2

Kaźmierczak‐Siedlecka, K., Daca, A., Fic, M., Van De Wetering, T., Folwarski, M., & Makarewicz, W. (2020). Therapeutic methods of gut microbiota modification in colorectal cancer management—Fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes, 11, 1518–1530. https://doi.org/10.1080/19490976.2020.1764309

Proença, I. M., Allegretti, J. R., Bernardo, W. M., De Moura, D. T. H., Ponte Neto, A. M., Matsubayashi, C. O., Flor, M. M., Kotinda, A. P. S. T., & De Moura, E. G. H. (2020). Fecal microbiota transplantation improves metabolic syndrome parameters: Systematic review with meta‐analysis based on randomized clinical trials. Nutrition Research, 83, 1–14. https://doi.org/10.1016/j.nutres.2020.06.018

Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez‐Gili, L., Punčochář, M., Ernst, S., Logan, D., Belanger, K., Esfahani, K., Richard, C., Ninkov, M., Piccinno, G., Armanini, F., Pinto, F., … Maleki Vareki, S. (2023). Fecal microbiota transplantation plus anti‐PD‐1 immunotherapy in advanced melanoma: A phase I trial. Nature Medicine, 29, 2121–2132. https://doi.org/10.1038/s41591‐023‐02453‐x

Craven, L. J., Nair Parvathy, S., Tat‐Ko, J., Burton, J. P., & Silverman, M. S. (2017). Extended screening costs associated with selecting donors for fecal microbiota transplantation for treatment of metabolic syndrome‐associated diseases. Open Forum Infectious Diseases, 4, ofx243. https://doi.org/10.1093/ofid/ofx243

Danne, C., Rolhion, N., & Sokol, H. (2021). Recipient factors in faecal microbiota transplantation: One stool does not fit all. Nature Reviews Gastroenterology & Hepatology, 18, 503–513. https://doi.org/10.1038/s41575‐021‐00441‐5

Kazemian, N., Ramezankhani, M., Sehgal, A., Khalid, F. M., Kalkhoran, A. H. Z., Narayan, A., Wong, G. K., Kao, D., & Pakpour, S. (2020). The trans‐kingdom battle between donor and recipient gut microbiome influences fecal microbiota transplantation outcome. Scientific Reports, 10, 18349. https://doi.org/10.1038/s41598‐020‐75162‐x

Daisley, B. A., Koenig, D., Engelbrecht, K., Doney, L., Hards, K., Al, K. F., Reid, G., & Burton, J. P. (2021). Emerging connections between gut microbiome bioenergetics and chronic metabolic diseases. Cell Reports, 37, 110087. https://doi.org/10.1016/j.celrep.2021.110087

Schmidt, T. S. B., Li, S. S., Maistrenko, O. M., Akanni, W., Coelho, L. P., Dolai, S., Fullam, A., Glazek, A. M., Hercog, R., Herrema, H., Jung, F., Kandels, S., Orakov, A., Thielemann, R., Von Stetten, M., Van Rossum, T., Benes, V., Borody, T. J., De Vos, W. M., … Bork, P. (2022). Drivers and determinants of strain dynamics following fecal microbiota transplantation. Nature Medicine, 28, 1902–1912. https://doi.org/10.1038/s41591‐022‐01913‐0

Tvede, M., & Rask‐Madsen, J. (1989). Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet, 333, 1156–1160. https://doi.org/10.1016/s0140‐6736(89)92749‐9

Petrof, E. O., Claud, E. C., Gloor, G. B., & Allen‐Vercoe, E. (2013). Microbial ecosystems therapeutics: A new paradigm in medicine? Beneficial Microbes, 4, 53–65. https://doi.org/10.3920/BM2012.0039

Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen‐Vercoe, E. (2013). Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome, 1, 3. https://doi.org/10.1186/2049‐2618‐1‐3

Kao, D., Wong, K., Franz, R., Cochrane, K., Sherriff, K., Chui, L., Lloyd, C., Roach, B., Bai, A. D., Petrof, E. O., & Allen‐Vercoe, E. (2021). The effect of a microbial ecosystem therapeutic (MET‐2) on recurrent Clostridioides difficile infection: A phase 1, open‐label, single‐group trial. The Lancet Gastroenterology & Hepatology, 6, 282–291. https://doi.org/10.1016/S2468‐1253(21)00007‐8

Chinna Meyyappan, A., Sgarbossa, C., Vazquez, G., Bond, D. J., Müller, D. J., & Milev, R. (2021). The safety and efficacy of microbial ecosystem therapeutic‐2 in people with major depression: Protocol for a phase 2, double‐blind, placebo‐controlled study. JMIR Research Protocols, 10, e31439. https://doi.org/10.2196/31439

Spreafico, A., Heirali, A. A., Araujo, D. V., Tan, T. J., Oliva, M., Schneeberger, P. H. H., Chen, B., Wong, M. K., Stayner, L.‐A., Hansen, A. R., Saibil, S. D., Wang, B. X., Cochrane, K., Sherriff, K., Allen‐Vercoe, E., Xu, W., Siu, L. L., & Coburn, B. (2023). First‐in‐class microbial ecosystem therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4‐IO trial). Annals of Oncology, 34, 520–530. https://doi.org/10.1016/j.annonc.2023.02.011

Dsouza, M., Menon, R., Crossette, E., Bhattarai, S. K., Schneider, J., Kim, Y.‐G., Reddy, S., Caballero, S., Felix, C., Cornacchione, L., Hendrickson, J., Watson, A. R., Minot, S. S., Greenfield, N., Schopf, L., Szabady, R., Patarroyo, J., Smith, W., Harrison, P., … Norman, J. M. (2022). Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host & Microbe, 30, 583–598. https://doi.org/10.1016/j.chom.2022.03.016

Louie, T., Golan, Y., Khanna, S., Bobilev, D., Erpelding, N., Fratazzi, C., Carini, M., Menon, R., Ruisi, M., Norman, J. M., Faith, J. J., Olle, B., Li, M., Silber, J. L., & Pardi, D. S. (2023). VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: A randomized clinical trial. Jama, 329, 1356–1366. https://doi.org/10.1001/jama.2023.4314

Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. L., Diao, L., Bryant, J. A., Sims, M., Kraft, C. S., Cohen, S. H., Berenson, C. S., Korman, L. Y., Ford, C. B., Litcofsky, K. D., Lombardo, M.‐J., Wortman, J. R., Wu, H., Auniņš, J. G., Mcchalicher, C. W. J., Winkler, J. A., … Von Moltke, L. (2022). SER‐109, an oral microbiome therapy for recurrent Clostridioides difficile infection. New England Journal of Medicine, 386, 220–229. https://doi.org/10.1056/NEJMoa2106516

Koopman, N., Remijas, L., Seppen, J., Setlow, P., & Brul, S. (2022). Mechanisms and applications of bacterial sporulation and germination in the intestine. International Journal of Molecular Sciences, 23, 3405. https://doi.org/10.3390/ijms23063405

Khanna, S., Sims, M., Louie, T. J., Fischer, M., Laplante, K., Allegretti, J., Hasson, B. R., Fonte, A. T., Mcchalicher, C., Ege, D. S., Bryant, J. A., Straub, T. J., Ford, C. B., Henn, M. R., Wang, E. E. L., Von Moltke, L., & Wilcox, M. H. (2022). SER‐109: An oral investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infection (rCDI). Antibiotics (Basel), 11, 1234. https://doi.org/10.3390/antibiotics11091234

Shin, N. R., Whon, T. W., & Bae, J. W. (2015). Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends in Biotechnology, 33, 496–503. https://doi.org/10.1016/j.tibtech.2015.06.011

Rooney, A. M., Cochrane, K., Fedsin, S., Yao, S., Anwer, S., Dehmiwal, S., Hota, S., Poutanen, S., Allen‐Vercoe, E., Coburn, B., Allard, J., Croitoru, K., Gaisano, H., Guttman, D., Taylor, V., Philpott, D., & Winer, D. (2023). A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection. MBio, 14, e0348222. https://doi.org/10.1128/mbio.03482‐22

Straub, T. J., Lombardo, M.‐J., Bryant, J. A., Diao, L., Lodise, T. P., Freedberg, D. E., Wortman, J. R., Litcofsky, K. D., Hasson, B. R., Mcgovern, B. H., Ford, C. B., & Henn, M. R. (2024). Impact of a purified microbiome therapeutic on abundance of antimicrobial resistance genes in patients with recurrent Clostridioides difficile infection. Clinical Infectious Diseases, 78, 833–841. https://doi.org/10.1093/cid/ciad636

Mcgovern, B. H., Ford, C. B., Henn, M. R., Pardi, D. S., Khanna, S., Hohmann, E. L., O'brien, E. J., Desjardins, C. A., Bernardo, P., Wortman, J. R., Lombardo, M.‐J., Litcofsky, K. D., Winkler, J. A., Mcchalicher, C. W. J., Li, S. S., Tomlinson, A. D., Nandakumar, M., Cook, D. N., Pomerantz, R. J., … Trucksis, M. (2021). SER‐109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: Lessons learned from a phase 2 trial. Clinical Infectious Diseases, 72, 2132–2140. https://doi.org/10.1093/cid/ciaa387

Wilde, J., Boyes, R., Robinson, A. V., Daisley, B. A., Botschner, A. J., Brettingham, D. J. L., Macpherson, C. V., Mallory, E., & Allen‐Vercoe, E. (2024). Assessing phage‐host population dynamics by reintroducing virulent viruses to synthetic microbiomes. Cell Host & Microbe, 32, 768–778. https://doi.org/10.1016/j.chom.2024.04.001

Benech, N., Barbut, F., Fitzpatrick, F., Krutova, M., Davies, K., Druart, C., Cordaillat‐Simmons, M., Heritage, J., Guery, B., Kuijper, E., ESGCD and ESGHAMI. (2024). Update on microbiota‐derived therapies for recurrent Clostridioides difficile infections. Clinical Microbiology and Infection, 30, 462–468. https://doi.org/10.1016/j.cmi.2023.12.007

Ma, J., Lyu, Y., Liu, X., Jia, X., Cui, F., Wu, X., Deng, S., & Yue, C. (2022). Engineered probiotics. Microbial cell factories, 21, 72. https://doi.org/10.1186/s12934‐022‐01799‐0

Huang, Y., Lin, X., Yu, S., Chen, R., & Chen, W. (2022). Intestinal engineered probiotics as living therapeutics: Chassis selection, colonization enhancement, gene circuit design, and biocontainment. ACS Synthetic Biology, 11, 3134–3153. https://doi.org/10.1021/acssynbio.2c00314

Murali, S. K., & Mansell, T. J. (2024). Next generation probiotics: Engineering live biotherapeutics. Biotechnology Advances, 72, 108336. https://doi.org/10.1016/j.biotechadv.2024.108336

Drolia, R., Amalaradjou, M. A. R., Ryan, V., Tenguria, S., Liu, D., Bai, X., Xu, L., Singh, A. K., Cox, A. D., Bernal‐Crespo, V., Schaber, J. A., Applegate, B. M., Vemulapalli, R., & Bhunia, A. K. (2020). Receptor‐targeted engineered probiotics mitigate lethal listeria infection. Nature Communications, 11, 6344. https://doi.org/10.1038/s41467‐020‐20200‐5

Vockley, J., Sondheimer, N., Puurunen, M., Diaz, G. A., Ginevic, I., Grange, D. K., Harding, C., Northrup, H., Phillips, J. A., Searle, S., Thomas, J. A., Zori, R., Denney, W. S., Ernst, S. L., Humphreys, K., Mcwhorter, N., Kurtz, C., & Brennan, A. M. (2023). Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: A phase 2 clinical trial. Nature Metabolism, 5, 1685–1690. https://doi.org/10.1038/s42255‐023‐00897‐6

Lubkowicz, D., Horvath, N. G., James, M. J., Cantarella, P., Renaud, L., Bergeron, C. G., Shmueli, R. B., Anderson, C., Gao, J.‐R., Kurtz, C. B., Perreault, M., Charbonneau, M. R., Isabella, V. M., & Hava, D. L. (2022). An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria. Molecular Systems Biology, 18, e10539. https://doi.org/10.15252/msb.202110539

Kurtz, C. B., Millet, Y. A., Puurunen, M. K., Perreault, M., Charbonneau, M. R., Isabella, V. M., Kotula, J. W., Antipov, E., Dagon, Y., Denney, W. S., Wagner, D. A., West, K. A., Degar, A. J., Brennan, A. M., & Miller, P. F. (2019). An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose‐dependent exposure in healthy humans. Science Translational Medicine, 11, eaau7975. https://doi.org/10.1126/scitranslmed.aau7975

Palmer, J. D., Piattelli, E., McCormick, B. A., Silby, M. W., Brigham, C. J., & Bucci, V. (2018). Engineered probiotic for the inhibition of salmonella via tetrathionate‐induced production of microcin H47. ACS Infectious Diseases, 4, 39–45. https://doi.org/10.1021/acsinfecdis.7b00114

Lan, Y. J., Tan, S. I., Cheng, S. Y., Ting, W. W., Xue, C. F., Lin, T. H., Cai, M. Z., Chen, P. T., & Ng, I. S. (2021). Development of Nissle 1917 derivative by CRISPR/Cas9 and application for gamma‐aminobutyric acid (GABA) production in antibiotic‐free system. Biochemical Engineering Journal, 168, 107952. https://doi.org/10.1016/j.bej.2021.107952

Canale, F. P., Basso, C., Antonini, G., Perotti, M., Li, N., Sokolovska, A., Neumann, J., James, M. J., Geiger, S., Jin, W., Theurillat, J.‐P., West, K. A., Leventhal, D. S., Lora, J. M., Sallusto, F., & Geiger, R. (2021). Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature, 598, 662–666. https://doi.org/10.1038/s41586‐021‐04003‐2

Cruz, K. C. P., Enekegho, L. O., & Stuart, D. T. (2022). Bioengineered probiotics: Synthetic biology can provide live cell therapeutics for the treatment of foodborne diseases. Frontiers in Bioengineering and Biotechnology, 10, 890479. https://doi.org/10.3389/fbioe.2022.890479

Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., Petrova, M. I., Collado, M. C., Morelli, L., Montoya, G. A., Szajewska, H., Tancredi, D. J., & Sanders, M. E. (2023). Emerging issues in probiotic safety: 2023 Perspectives. Gut Microbes, 15, 2185034. https://doi.org/10.1080/19490976.2023.2185034

Yoon, H. S., Cho, C. H., Yun, M. S., Jang, S. J., You, H. J., Kim, J.‐H., Han, D., Cha, K. H., Moon, S. H., Lee, K., Kim, Y.‐J., Lee, S.‐J., Nam, T.‐W., & Ko, G. (2021). Akkermansia muciniphila secretes a glucagon‐like peptide‐1‐inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nature Microbiology, 6, 563–573. https://doi.org/10.1038/s41564‐021‐00880‐5

Davey, L. E., Malkus, P. N., Villa, M., Dolat, L., Holmes, Z. C., Letourneau, J., Ansaldo, E., David, L. A., Barton, G. M., & Valdivia, R. H. (2023). A genetic system for Akkermansia muciniphila reveals a role for mucin foraging in gut colonization and host sterol biosynthesis gene expression. Nature Microbiology, 8, 1450–1467. https://doi.org/10.1038/s41564‐023‐01407‐w

Quévrain, E., Maubert, M. A., Michon, C., Chain, F., Marquant, R., Tailhades, J., Miquel, S., Carlier, L., Bermúdez‐Humarán, L. G., Pigneur, B., Lequin, O., Kharrat, P., Thomas, G., Rainteau, D., Aubry, C., Breyner, N., Afonso, C., Lavielle, S., Grill, J.‐P., … Seksik, P. (2016). Identification of an anti‐inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut, 65, 415–425. https://doi.org/10.1136/gutjnl‐2014‐307649

Fekry, M. I., Engels, C., Zhang, J., Schwab, C., Lacroix, C., Sturla, S. J., & Chassard, C. (2016). The strict anaerobic gut microbe Eubacterium hallii transforms the carcinogenic dietary heterocyclic amine 2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine (PhIP). Environmental Microbiology Reports, 8, 201–209. https://doi.org/10.1111/1758‐2229.12369

Funabashi, M., Grove, T. L., Wang, M., Varma, Y., McFadden, M. E., Brown, L. C., Guo, C., Higginbottom, S., Almo, S. C., & Fischbach, M. A. (2020). A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature, 582, 566–570. https://doi.org/10.1038/s41586‐020‐2396‐4

Arnold, J., Glazier, J., & Mimee, M. (2023). Genetic engineering of resident bacteria in the gut microbiome. Journal of Bacteriology, 205, e0012723. https://doi.org/10.1128/jb.00127‐23

Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez‐Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., Heath, A. C., Warner, B., Reeder, J., Kuczynski, J., Caporaso, J. G., Lozupone, C. A., Lauber, C., Clemente, J. C., Knights, D., … Gordon, J. I. (2012). Human gut microbiome viewed across age and geography. Nature, 486, 222–227. https://doi.org/10.1038/nature11053

Carter, M. M., Olm, M. R., Merrill, B. D., Dahan, D., Tripathi, S., Spencer, S. P., Yu, F. B., Jain, S., Neff, N., Jha, A. R., Sonnenburg, E. D., & Sonnenburg, J. L. (2023). Ultra‐deep sequencing of Hadza hunter‐gatherers recovers vanishing gut microbes. Cell, 186, 3111–3124. https://doi.org/10.1016/j.cell.2023.05.046

Conteville, L. C., Oliveira‐Ferreira, J., & Vicente, A. C. P. (2019). Gut microbiome biomarkers and functional diversity within an amazonian semi‐nomadic hunter‐gatherer group. Frontiers in Microbiology, 10, 1743. https://doi.org/10.3389/fmicb.2019.01743

Obregon‐Tito, A. J., Tito, R. Y., Metcalf, J., Sankaranarayanan, K., Clemente, J. C., Ursell, L. K., Zech Xu, Z., Van Treuren, W., Knight, R., Gaffney, P. M., Spicer, P., Lawson, P., Marin‐Reyes, L., Trujillo‐Villarroel, O., Foster, M., Guija‐Poma, E., Troncoso‐Corzo, L., Warinner, C., Ozga, A. T., & Lewis, C. M. (2015). Subsistence strategies in traditional societies distinguish gut microbiomes. Nature Communications, 6, 6505. https://doi.org/10.1038/ncomms7505

Blaser, M. J., & Falkow, S. (2009). What are the consequences of the disappearing human microbiota? Nature Reviews Microbiology, 7, 887–894. https://doi.org/10.1038/nrmicro2245

Wibowo, M. C., Yang, Z., Borry, M., Hübner, A., Huang, K. D., Tierney, B. T., Zimmerman, S., Barajas‐Olmos, F., Contreras‐Cubas, C., García‐Ortiz, H., Martínez‐Hernández, A., Luber, J. M., Kirstahler, P., Blohm, T., Smiley, F. E., Arnold, R., Ballal, S. A., Pamp, S. J., Russ, J., … Kostic, A. D. (2021). Reconstruction of ancient microbial genomes from the human gut. Nature, 594, 234–239. https://doi.org/10.1038/s41586‐021‐03532‐0

Fragiadakis, G. K., Smits, S. A., Sonnenburg, E. D., Van Treuren, W., Reid, G., Knight, R., Manjurano, A., Changalucha, J., Dominguez‐Bello, M. G., Leach, J., & Sonnenburg, J. L. (2019). Links between environment, diet, and the hunter‐gatherer microbiome. Gut Microbes, 10, 216–227. https://doi.org/10.1080/19490976.2018.1494103

Chen, Y.‐H., Yeung, F., Lacey, K. A., Zaldana, K., Lin, J.‐D., Bee, G. C. W., Mccauley, C., Barre, R. S., Liang, S.‐H., Hansen, C. B., Downie, A. E., Tio, K., Weiser, J. N., Torres, V. J., Bennett, R. J., Loke, P. N., Graham, A. L., & Cadwell, K. (2023). Rewilding of laboratory mice enhances granulopoiesis and immunity through intestinal fungal colonization. Science Immunology, 8, eadd6910. https://doi.org/10.1126/sciimmunol.add6910

Blaser, M. J. (2018). The past and future biology of the human microbiome in an age of extinctions. Cell, 172, 1173–1177. https://doi.org/10.1016/j.cell.2018.02.040

Belkhou, C., Tadeo, R. T., Bacigalupe, R., Valles‐Colomer, M., Chaffron, S., Joossens, M., Obregon, A., Marín Reyes, L., Trujillo, O., Huys, G. R. B., & Raes, J. (2021). Treponema peruense sp. nov., a commensal spirochaete isolated from human faeces. International Journal of Systematic and Evolutionary Microbiology, 71, 005050. https://doi.org/10.1099/ijsem.0.005050

Chang, H.‐W., Lee, E. M., Wang, Y., Zhou, C., Pruss, K. M., Henrissat, S., Chen, R. Y., Kao, C., Hibberd, M. C., Lynn, H. M., Webber, D. M., Crane, M., Cheng, J., Rodionov, D. A., Arzamasov, A. A., Castillo, J. J., Couture, G., Chen, Y., Balcazo, N. P., … Gordon, J. I. (2024). Prevotella copri and microbiota members mediate the beneficial effects of a therapeutic food for malnutrition. Nature Microbiology, 9, 922–937. https://doi.org/10.1038/s41564‐024‐01628‐7

Kovatcheva‐Datchary, P., Nilsson, A., Akrami, R., Lee, Y. S., De Vadder, F., Arora, T., Hallen, A., Martens, E., Björck, I., & Bäckhed, F. (2015). Dietary fiber‐induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metabolism, 22, 971–982. https://doi.org/10.1016/j.cmet.2015.10.001

Gong, J., Zhang, Q., Hu, R., Yang, X., Fang, C., Yao, L., Lv, J., Wang, L., Shi, M., Zhang, W., Ma, S., Xiang, H., Zhang, H., Hou, D.‐X., Yin, Y., He, J., Peng, L., & Wu, S. (2024). Effects of Prevotella copri on insulin, gut microbiota and bile acids. Gut Microbes, 16, 2340487. https://doi.org/10.1080/19490976.2024.2340487

Jiang, L., Shang, M., Yu, S., Liu, Y., Zhang, H., Zhou, Y., Wang, M., Wang, T., Li, H., Liu, Z., & Zhang, X. (2022). A high‐fiber diet synergizes with Prevotella copri and exacerbates rheumatoid arthritis. Cellular & Molecular Immunology, 19, 1414–1424. https://doi.org/10.1038/s41423‐022‐00934‐6

Wen, C., Zheng, Z., Shao, T., Liu, L., Xie, Z., Le Chatelier, E., He, Z., Zhong, W., Fan, Y., Zhang, L., Li, H., Wu, C., Hu, C., Xu, Q., Zhou, J., Cai, S., Wang, D., Huang, Y., Breban, M., … Ehrlich, S. D. (2017). Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis. Genome Biology, 18, 142. https://doi.org/10.1186/s13059‐017‐1271‐6

Ke, S., Weiss, S. T., & Liu, Y. Y. (2022). Rejuvenating the human gut microbiome. Trends in Molecular Medicine, 28, 619–630. https://doi.org/10.1016/j.molmed.2022.05.005

Chen, L., Wang, D., Garmaeva, S., Kurilshikov, A., Vich Vila, A., Gacesa, R., Sinha, T., Segal, E., Weersma, R. K., Wijmenga, C., Zhernakova, A., & Fu, J. (2021). The long‐term genetic stability and individual specificity of the human gut microbiome. Cell, 184, 2302–2315. https://doi.org/10.1016/j.cell.2021.03.024

Ferreiro, A. L., Choi, J., Ryou, J., Newcomer, E. P., Thompson, R., Bollinger, R. M., Hall‐Moore, C., Ndao, I. M., Sax, L., Benzinger, T. L. S., Stark, S. L., Holtzman, D. M., Fagan, A. M., Schindler, S. E., Cruchaga, C., Butt, O. H., Morris, J. C., Tarr, P. I., Ances, B. M., & Dantas, G. (2023). Gut microbiome composition may be an indicator of preclinical Alzheimer's disease. Science Translational Medicine, 15, eabo2984. https://doi.org/10.1126/scitranslmed.abo2984

Reitmeier, S., Kiessling, S., Clavel, T., List, M., Almeida, E. L., Ghosh, T. S., Neuhaus, K., Grallert, H., Linseisen, J., Skurk, T., Brandl, B., Breuninger, T. A., Troll, M., Rathmann, W., Linkohr, B., Hauner, H., Laudes, M., Franke, A., Le Roy, C. I., … Haller, D. (2020). Arrhythmic gut microbiome signatures predict risk of type 2 diabetes. Cell Host & Microbe, 28, 258–272. https://doi.org/10.1016/j.chom.2020.06.004

Berry, S. E., Valdes, A. M., Drew, D. A., Asnicar, F., Mazidi, M., Wolf, J., Capdevila, J., Hadjigeorgiou, G., Davies, R., Al Khatib, H., Bonnett, C., Ganesh, S., Bakker, E., Hart, D., Mangino, M., Merino, J., Linenberg, I., Wyatt, P., Ordovas, J. M., … Spector, T. D. (2020). Human postprandial responses to food and potential for precision nutrition. Nature Medicine, 26, 964–973. https://doi.org/10.1038/s41591‐020‐0934‐0

Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., Ben‐Yacov, O., Lador, D., Avnit‐Sagi, T., Lotan‐Pompan, M., Suez, J., Mahdi, J. A., Matot, E., Malka, G., Kosower, N., Rein, M., Zilberman‐Schapira, G., Dohnalová, L., Pevsner‐Fischer, M., … Segal, E. (2015). Personalized nutrition by prediction of glycemic responses. Cell, 163, 1079–1094. https://doi.org/10.1016/j.cell.2015.11.001

Korem, T., Zeevi, D., Zmora, N., Weissbrod, O., Bar, N., Lotan‐Pompan, M., Avnit‐Sagi, T., Kosower, N., Malka, G., Rein, M., Suez, J., Goldberg, B. Z., Weinberger, A., Levy, A. A., Elinav, E., & Segal, E. (2017). Bread affects clinical parameters and induces gut microbiome‐associated personal glycemic responses. Cell Metabolism, 25, 1243–1253. https://doi.org/10.1016/j.cmet.2017.05.002

Suez, J., Cohen, Y., Valdés‐Mas, R., Mor, U., Dori‐Bachash, M., Federici, S., Zmora, N., Leshem, A., Heinemann, M., Linevsky, R., Zur, M., Ben‐Zeev Brik, R., Bukimer, A., Eliyahu‐Miller, S., Metz, A., Fischbein, R., Sharov, O., Malitsky, S., Itkin, M., … Elinav, E. (2022). Personalized microbiome‐driven effects of non‐nutritive sweeteners on human glucose tolerance. Cell, 185, 3307–3328. https://doi.org/10.1016/j.cell.2022.07.016

Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017). Chemical transformation of xenobiotics by the human gut microbiota. Science, 356, eaag2770. https://doi.org/10.1126/science.aag2770

Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013). Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell, 152, 39–50. https://doi.org/10.1016/j.cell.2012.10.052

de Jong, S. E., Olin, A., & Pulendran, B. (2020). The impact of the microbiome on immunity to vaccination in humans. Cell Host & Microbe, 28, 169–179. https://doi.org/10.1016/j.chom.2020.06.014

Ratiner, K., Ciocan, D., Abdeen, S. K., & Elinav, E. (2024). Utilization of the microbiome in personalized medicine. Nature Reviews Microbiology, 22, 291–308. https://doi.org/10.1038/s41579‐023‐00998‐9

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Subventions

Informations de copyright

Références

Auteurs

Brendan A Daisley (BA)

Emma Allen-Vercoe (E)

Classifications MeSH